On August 22 after market close, Mgi Tech Co.,Ltd. (688114.SH) released its interim financial report for 2025. The report shows that in the first half of 2025, the company achieved main business revenue of 1.091 billion yuan, with net profit attributable to parent company shareholders reducing losses by 65.28% year-over-year. The whole genome long-read sequencing business, as the company's core business segment, saw over 700 new instrument sales in the first half, representing a 60.35% year-over-year increase and setting a new record high for the same period. Beyond business scale growth, Mgi Tech Co.,Ltd.'s quality improvement and efficiency enhancement achievements were equally remarkable. Through dual-driven technology innovation and lean management, the company achieved synchronized advancement in business scale and operational quality. In the first half of 2025, the company's non-GAAP net profit attributable to parent company shareholders narrowed losses by 37.55% year-over-year. Period expenses (excluding financial expenses) totaled 827 million yuan, down 17.04% compared to the same period last year. In terms of production capacity and supply chain, leveraging its leading position as a "gene sequencer industry chain leader," the company collaborated with over 50 suppliers to tackle core raw materials challenges, driving overall industry chain efficiency improvements of 25% and achieving dual breakthroughs in high localization rates and industrial synergy. The company's global spare parts delivery punctuality rate steadily improved to 90%, with China region reaching 91.04%, maintaining industry leadership with a 72-hour delivery cycle. The three-dimensional efforts in technological breakthroughs, management optimization, and supply chain collaboration have built a solid foundation for the company's long-term value creation and operational resilience. Currently, artificial intelligence technology is becoming a key driving force for industry transformation. In the first half of this year, Mgi Tech Co.,Ltd. continued advancing its Genomics Laboratory Intelligence (GLI) business upgrade, comprehensively reconstructing its laboratory automation business through AI technology and accelerating AI-driven software tool development to provide underlying support for intelligent ecosystems. At the technical level, based on deep insights into business logic and customer scenarios, the company has built AI closed-loop solutions covering the entire "Design-Build-Test-Learn" process, pioneering a new wet-dry closed-loop model where "AI brain" designs autonomously and "robotic hands" execute precisely, significantly compressing traditional research and development cycles from weeks and driving laboratories' transition from manual experience-based decision-making to data-driven approaches.
Comments